nach oben

Journal of Behavioral Medicine

Erschienen in:

01.06.2010

Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition

verfasst von: Jared M. Bruce, Laura M. Hancock, Peter Arnett, Sharon Lynch

Erschienen in: Journal of Behavioral Medicine | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the present study was to prospectively examine the association between treatment adherence and common neuropsychiatric symptoms in multiple sclerosis (MS). Patients underwent a thorough psychiatric and neuropsychological evaluation at the outset of the study. Patient adherence to disease modifying therapies was then tracked for 8 weeks using self-report, a medication diary, and an electronic monitoring device that recorded needle disposals. Results indicated that MS patients with current mood or anxiety disorders were almost five times as likely as MS patients with no psychiatric diagnosis to exhibit problems adhering to their disease modifying therapies. Poor adherence was also associated with memory difficulties, anxiety, depression, neuroticism, and low conscientiousness. Findings highlight the importance of conducting a thorough psychiatric and neuropsychological evaluation when clinicians suspect poor adherence to disease modifying therapies. Pharmacological or psychotherapeutic treatment of mood/anxiety disorders, use of scheduled reminders, and/or increased organization and structure may lead to improved treatment adherence in MS.

Albert, S. M., Flater, S. R., Clouse, R., Todak, G., Stern, Y., & Marder, K. (2003). Medication management skill in HIV: I. Evidence for adaptation of medication management strategies in people with cognitive impairment. II. Evidence for a pervasive lay model of medication efficacy. AIDS and Behavior, 7(3), 329–338.CrossRefPubMed

Altice, F., & Friedland, G. (1998). The era of adherence to HIV therapy. Annals of Internal Medicine, 129, 503–505.PubMed

Arnett, P. A. (2003). Neuropsychological presentation and treatment of demyelinating disorders. In U. K. P. Halligan & J. Marshall (Eds.), Handbook of Clinical Neuropsychology (pp. 528–543). Oxford: Oxford University Press.

Beck, A. T., Steer, R. A., & Brown, G. K. (2000). BDI-FastScreen for Medical Patients Manual. San Antonio: The Psychological Corporation.

Benedict, R. H., Fishman, I., McClellan, M. M., Bakshi, R., & Weinstock-Guttman, B. (2003). Validity of the beck depression inventory-fast screen in multiple sclerosis. Multiple Sclerosis, 9(4), 393–396.CrossRefPubMed

Benedict, R. H. B., Priore, R. L., Miller, C., Munschauer, F., & Jacobs, L. (2001). Personality disorder in multiple sclerosis correlates with cognitive impairment. Journal of Neuropsychiatry and Clinical Neurosciences, 13, 70–76.PubMed

Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., et al. (2005). Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of Neurological Sciences, 231(1–2), 29–34.CrossRef

Berger, B. A., Hudmon, K. S., & Liang, H. (2004). Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change. Journal of the American Pharmacists Association, 44(4), 445–454.CrossRefPubMed

Bosworth, H. (2006). Medication Treatment Adherence. In H. Bosworth, E. Oddone, & M. Weinberger (Eds.), Patient Treatment Adherence: Concepts Interventions, and Measurement. London: Lawrence Erlbaum Associates.

Brauner, D., Muir, C., & Sachs, G. (2000). Treating nondementia illnesses in patients with dementia. Journal of the American Medical Association, 283(24), 3230–3235.CrossRefPubMed

Bruce, J. M., & Arnett, P. (2009). Clinical correlates of generalized worry in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 31(6), 698–705.CrossRefPubMed

Bruce, J. M., Hancock, L., Lynch, S. (2010). Objective adherence monitoring in MS: Initial validation and association with self-report. Multiple Sclerosis, 16(1), 112–120.CrossRefPubMed

Costa, P. T., & McCrae, R. R. (1992). Professional manual for the NEO PI-R and NEO-FFI.: Psychological Assessment Resources.

Cramer, J. (2004). A systematic review of adherence with medications for diabetes. Diabetes Care, 27(5), 1218–1224.CrossRefPubMed

Edwards, G. J. B., Leffler, D. A., Dennis, M. D., Franko, D. L., Blom-Hoffman, J., & Kelly, C. P. (2009). Psychological correlates of gluten free diet adherence in adults with celiac disease. Journal of Clinical Gastroenterology, 43(4), 301–306.CrossRef

Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994). The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21, 9–14.PubMed

Fraser, C., Morgante, L., Hadjimichael, O., & Vollmer, T. (2004). A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. Journal of Neuroscience Nursing, 36(3), 120–129.CrossRefPubMed

Goodin, D. S. (2008). Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology, 71(24 Suppl 3), S8–S13.CrossRefPubMed

Grant, D. A., & Berg, E. A. (1948). A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem. Journal of Experimental Psychology, 38(4), 404–411.CrossRefPubMed

Haas, J., & Firzlaff, M. (2005). Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology, 12(6), 425–431.CrossRefPubMed

Higginson, C. I., Arnett, P. A., & Voss, W. D. (2000). The ecological validity of clinical tests of memory and attention in multiple sclerosis. Archives of Clinical Neuropsychology, 15, 185–204.PubMed

Insel, K., Morrow, D., Brewer, B., & Figueredo, A. (2006). Executive function, working memory, and medication adherence among older adults. Journal of Gerontology Series B: Psychological Sciences and Social Sciences, 61(2), P102–P107.

Inui, T. S., Carter, W. B., & Pecoraro, R. E. (1981). Screening for noncompliance among patients with hypertension: is self-report the best available measure? Medical Care, 19(10), 1061–1064.CrossRefPubMed

Korostil, M., & Feinstein, A. (2007). Anxiety disorders and their clinical correlates in multiple sclerosis patients. Multiple Sclerosis, 13(1), 67–72.CrossRefPubMed

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33, 1444–1452.PubMed

Lezak, M. (1995). Neuropsychological assessment, third edition (3rd ed.). New York: Oxford University Press.

Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968–977.PubMed

Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46, 907–911.PubMed

Milanese, C., La Mantia, L., Palumbo, R., Martinelli, V., Murialdo, A., Zaffaroni, M., et al. (2003). A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. Journal of Neurology, Neurosurgery and Psychiatry, 74(12), 1689–1692.CrossRef

Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23(2), 125–132.CrossRefPubMed

Mohr, D., & Cox, D. (2001). Multiple sclerosis: empirical literature for the clinical health psychologist. Journal of Clinical Psychology, 57(4), 479–499.CrossRefPubMed

Newby, L., LaPointe, N., Chen, A., Kramer, J., Hammill, B., DeLong, E., et al. (2006). Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 113, 203–212.CrossRefPubMed

O’Rourke, K. E., & Hutchinson, M. (2005). Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Multiple Sclerosis, 11(1), 46–50.CrossRefPubMed

Pampallona, S., Bollini, P., Tibaldi, G., Kupelnick, B., & Munizza, C. (2002). Patient adherence in the treatment of depression. British Journal of Psychiatry, 180, 104–109.CrossRefPubMed

Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology, 58(6), 840–846.CrossRefPubMed

Portaccio, E., Zipoli, V., Siracusa, G., Sorbi, S., & Amato, M. P. (2008). Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. European Neurology, 59(3–4), 131–135.CrossRefPubMed

Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991a). Cognitive dysfunction in multiple sclerosis. 1. Frequency, patterns, and prediction. Neurology, 41, 685–691.PubMed

Rao, S. M., Leo, G. J., Ellington, L., Nauertz, T., Bernardin, L., & Unverzagt, F. (1991b). Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology, 41, 692–696.PubMed

Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M. J., et al. (2005). Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11(3), 306–309.CrossRefPubMed

Ruggieri, R. M., Settipani, N., Viviano, L., Attanasio, M., Giglia, L., Almasio, P., et al. (2003). Long-term interferon-beta treatment for multiple sclerosis. Neurological Science, 24(5), 361–364.CrossRef

Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(20), 22–33.PubMed

Smith, A. (1982). Symbol Digit Modalities Test (SDMT) Manual (Revised). Los Angeles: Western Psychological Services.

Spielberger, C. D. (1983). Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press.

Stein, M., Cantrell, C., Sokol, M., Eaddy, M., & Shah, M. (2006). Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatric Services, 57(5), 673–680.CrossRefPubMed

Stilley, C. S., Sereika, S., Muldoon, M. F., Ryan, C. M., & Dunbar-Jacob, J. (2004). Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Annals of Behavioral Medicine, 27(2), 117–124.CrossRefPubMed

Stroop, J. R. (1935). Studies of interference in serial verbal reactions. Journal of Experimental Psychology, 18, 643–662.CrossRef

Tremlett, H. L., & Oger, J. (2003). Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology, 61(4), 551–554.PubMed

Turner, A. P., Kivlahan, D. R., Sloan, A. P., & Haselkorn, J. K. (2007). Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Multiple Sclerosis, 13(9), 1146–1152.CrossRefPubMed

Van Houtven, C., Weinberger, M., & Carey, T. (2006). Implications of nonadherence for economic evaluation and health policy. In H. Bosworth, E. Oddone, & M. Weinberger (Eds.), Patient Treatment Adherence: Concepts, Interventions, and Measurement. London: Lawrence Erlbaum Associates.

Wechsler, D. (1997). Wechsler Adult Intelligence Scale (3rd ed.). San Antonio: The Psychological Corporation.

Wetherell, J., & Unutzer, J. (2003). Adherence to treatment for geriatric depression and anxiety. CNS Spectrums, 8(12 supplement 3), 48–59.PubMed

Woods, S. P., Moran, L. M., Dawson, M. S., Carey, C. L., & Grant, I. (2008). Psychometric characteristics of the memory for intentions screening test. The Clinical Neuropsychologist, 22(5), 864–878.CrossRefPubMed

World Health Organization. (2003). Adherence to Long-term Therapies: Evidence for Action. Geneva: WHO.

Zeller, A., Ramseier, E., Teagtmeyer, A., & Battegay, E. (2008). Patients’ self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertension Research, 31(11), 2037–2043.CrossRefPubMed

Titel: Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition
verfasst von: Jared M. Bruce
Laura M. Hancock
Peter Arnett
Sharon Lynch
Publikationsdatum: 01.06.2010
Verlag: Springer US
Erschienen in: Journal of Behavioral Medicine / Ausgabe 3/2010
Print ISSN: 0160-7715
Elektronische ISSN: 1573-3521
DOI: https://doi.org/10.1007/s10865-010-9247-y

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Coping self-efficacy as a mediator between catastrophizing and physical functioning: treatment target selection in an osteoarthritis sample

The influence of quality of life and depressed mood on smoking cessation among medically ill smokers

A typology of coping with Type 1 diabetes in emerging adulthood: associations with demographic, psychological, and clinical parameters

Stress generation over the course of breast cancer survivorship

Suppression of pain-related thoughts and feelings during pain-induction: sex differences in delayed pain responses

A comparison of the efficacy of an appearance-focused skin cancer intervention within indoor tanner subgroups identified by latent profile analysis

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie